Sanofi (SAN) Aandelenoverzicht
Sanofi, een bedrijf in de gezondheidszorg, houdt zich bezig met onderzoek, ontwikkeling, productie en marketing van therapeutische oplossingen in de Verenigde Staten, Europa en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 6/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 5/6 |
Beloningen
Risicoanalyse
SAN Community Fair Values
Create NarrativeSee what 222 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sanofi Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €75.81 |
| 52 Week Hoogtepunt | €91.15 |
| 52 Week Laag | €71.25 |
| Bèta | 0.28 |
| 1 maand verandering | 3.11% |
| 3 maanden verandering | -8.20% |
| 1 Jaar Verandering | -8.98% |
| 3 jaar verandering | -19.31% |
| 5 jaar verandering | -13.08% |
| Verandering sinds IPO | 82.24% |
Recent nieuws en updates
Narratiefupdate • Jul 02
SAN: Pipeline Approvals And R&D Execution Will Shape Future Share Support
Analysts have lifted the indicative fair value for Sanofi to €82.00 from €72.40, citing updated assumptions for revenue growth, profit margins and future P/E that are broadly in line with recent upward revisions to price targets seen across parts of the European market. Analyst Commentary Analysts covering Sanofi have framed the updated fair value in the context of broader reassessments across European equities, with the new €82.00 level positioned as an attempt to reflect current assumptions on growth, profitability and P/E multiples rather than a shift driven by any single catalyst.
Narratiefupdate • Jun 18
SAN: Future Upside Will Hinge On AI Execution Across R&D Workflows
Sanofi's analyst price target has been revised slightly to €96.70 from €97.10. This change reflects updated views on its revenue growth outlook, profit margin assumptions and a modestly adjusted future P/E multiple, according to recent analyst commentary.Recent updates
Narratiefupdate • Jul 02
SAN: Pipeline Approvals And R&D Execution Will Shape Future Share Support
Analysts have lifted the indicative fair value for Sanofi to €82.00 from €72.40, citing updated assumptions for revenue growth, profit margins and future P/E that are broadly in line with recent upward revisions to price targets seen across parts of the European market. Analyst Commentary Analysts covering Sanofi have framed the updated fair value in the context of broader reassessments across European equities, with the new €82.00 level positioned as an attempt to reflect current assumptions on growth, profitability and P/E multiples rather than a shift driven by any single catalyst.Narratiefupdate • Jun 18
SAN: Future Upside Will Hinge On AI Execution Across R&D Workflows
Sanofi's analyst price target has been revised slightly to €96.70 from €97.10. This change reflects updated views on its revenue growth outlook, profit margin assumptions and a modestly adjusted future P/E multiple, according to recent analyst commentary.Narratiefupdate • Jun 04
SAN: Future Upside Will Depend On AI Execution And R&D Pipeline Delivery
Analysts have nudged their fair value estimate for Sanofi higher from €95.53 to €97.10, citing slightly adjusted assumptions on discount rate, revenue growth, profit margins and future P/E as the basis for the updated price target. Analyst Commentary Bullish analysts framing the updated fair value for Sanofi around €97.10 are effectively signaling confidence that the company can execute in line with, or slightly ahead of, their refined assumptions on discount rate, revenue trajectory, margins and implied future P/E.Analyseartikel • May 04
Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings
Shareholders appeared unconcerned with Sanofi's ( EPA:SAN ) lackluster earnings report last week. We think that the...Narratiefupdate • Apr 22
SAN: Future Upside Will Rely On Pipeline Delivery And Margin Execution
Sanofi's analyst price target has been adjusted slightly lower to €95.53 from €96.10, as analysts factor in marginally higher revenue growth expectations, a modestly lower profit margin and a revised forward P/E assumption. Analyst Commentary Recent Street research on large European financials and cross border bank transactions offers a useful lens for thinking about how analysts might be framing Sanofi's current valuation reset and execution risks, even though the specific notes focus on banks rather than pharmaceuticals.
Nieuw narratief • Apr 14
Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade
Catalysts About Sanofi Sanofi is a global biopharma group focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Apr 07
SAN: Future Upside Will Rely On Pipeline Delivery And Margin Expansion
Analysts trimmed Sanofi's fair value estimate by €2.00 to €96.10, citing updated assumptions that include slightly different revenue growth, a higher profit margin profile, and a lower future P/E multiple. Analyst Commentary Recent Street research on European financials and cross border bank deals offers some reference points that investors can use when thinking about Sanofi's updated fair value and how sentiment can swing as assumptions change.Nieuw narratief • Mar 31
Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability
Catalysts About Sanofi Sanofi is a global biopharmaceutical company focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Mar 24
SAN: Future Upside Will Rely On Pipeline Execution And Margin Strength
Sanofi's analyst price target has been adjusted to €98.10 from €98.49 as analysts factor in slightly higher assumed revenue growth, stronger profit margins and a lower future P/E multiple in their updated models. Analyst Commentary Analysts updating their models for Sanofi are weighing the slightly higher revenue assumptions and stronger margin profile against a more conservative future P/E multiple.Narratiefupdate • Mar 09
SAN: Future Upside Will Rely On Pipeline Execution And Margin Resilience
Analysts have nudged their price target on Sanofi higher to €98.49, reflecting slightly firmer revenue growth assumptions and a nearly unchanged long-term profit margin and P/E outlook. Analyst Commentary Analysts covering Sanofi are broadly focused on how the updated €98.49 price target lines up with the company’s ability to execute on its plan, sustain its profit profile and justify its current P/E.Narratiefupdate • Feb 23
SAN: Future Upside Will Rely On Pipeline Delivery And Margin Stability
Analysts have trimmed their Sanofi price target slightly to €98.49. The change is tied to more cautious assumptions for revenue growth, profit margins and a modestly higher future P/E multiple.Narratiefupdate • Feb 09
SAN: Future Upside Will Depend On Pipeline Execution And Margin Resilience
Analysts have trimmed their Sanofi price targets slightly, with fair value moving from about €101 to about €99 as they factor in a modestly higher discount rate, slightly softer revenue growth assumptions around 3.6% and a marginally lower expected profit margin near 19.7%, paired with a future P/E closer to 12.8x. Analyst Commentary Recent updates to Sanofi valuation assumptions, including a modestly higher discount rate and slightly softer revenue and margin expectations, have led analysts to fine tune their views rather than overhaul them.Narratiefupdate • Jan 25
SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline
Analysts have trimmed their price target on Sanofi to reflect a fair value move from €102.77 to €100.96, citing updated assumptions around revenue growth, profit margins and future P/E levels. Analyst Commentary While the latest fair value trim for Sanofi is modest, it still reflects a tight range of outcomes that analysts see as reasonable based on current assumptions around growth, profitability and P/E levels.Narratiefupdate • Jan 11
SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline
Analysts have trimmed their fair value estimate for Sanofi from about €104.87 to roughly €102.77, pointing to slightly softer assumptions for revenue growth, profit margins and future P/E as key drivers of the updated price target outlook. Analyst Commentary Recent fair value adjustments for Sanofi sit against a backdrop of active price target revisions across European equities, including large financials, where several research desks have been updating their expectations.Narratiefupdate • Dec 25
SAN: Future Upside Will Depend On Pipeline Delivery And Cost Discipline
Analysts have trimmed their price target for Sanofi modestly, cutting their fair value estimate by about EUR 0.33 to roughly EUR 104.87. They cite slightly slower revenue growth, a softer profit margin profile, and a marginally higher future earnings multiple as the main factors behind this adjustment.Narratiefupdate • Dec 11
SAN: Future Returns Will Depend On Execution Of Late-Stage Pipeline
Analysts have nudged their fair value estimate for Sanofi slightly lower from EUR 106.26 to about EUR 105.20, citing marginally softer revenue growth assumptions, partially offset by a modestly stronger profit margin outlook and a slightly reduced forward P E multiple. Analyst Commentary Analyst sentiment on Sanofi remains broadly constructive, with recent fair value adjustments reflecting a more nuanced balance between growth ambitions and execution risks.Narratiefupdate • Nov 27
SAN: Future Momentum Will Depend On Execution Of New Pipeline Approvals
Sanofi's analyst price target has been modestly adjusted downward from $106.85 to $106.26. Analysts point to slight improvements in profit margin and future valuation metrics while maintaining a broadly stable outlook.Narratiefupdate • Nov 10
SAN: Forward Momentum Will Rely On Pipeline Success And Operational Execution
Sanofi's analyst price target saw a slight decrease to $106.85 from $106.90. Analysts cite moderating revenue growth expectations and a slightly higher discount rate impacting the updated valuation.Analyseartikel • Oct 31
We Think Sanofi's (EPA:SAN) Healthy Earnings Might Be Conservative
Sanofi's ( EPA:SAN ) recent earnings report didn't offer any surprises, with the shares unchanged over the last week...Narratiefupdate • Oct 27
Future Shareholder Returns Will Depend On Commercial Execution And Pipeline Momentum
Sanofi's analyst price target has been slightly lowered from €108.31 to €106.90. Analysts cite modest improvements in revenue growth and profit margin, but note a more conservative outlook for the company's future valuation.Rendement voor aandeelhouders
| SAN | FR Pharmaceuticals | FR Markt | |
|---|---|---|---|
| 7D | 1.0% | 1.4% | 1.5% |
| 1Y | -9.0% | -3.2% | 5.6% |
Rendement versus industrie: SAN presteerde slechter dan de French Pharmaceuticals -sector, die het afgelopen jaar een rendement van -3.2 % opleverde.
Rendement versus markt: SAN presteerde slechter dan French Market, dat het afgelopen jaar een rendement van 5.6 % opleverde.
Prijsvolatiliteit
| SAN volatility | |
|---|---|
| SAN Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in FR Market | 11.1% |
| 10% least volatile stocks in FR Market | 2.5% |
Stabiele aandelenkoers: SAN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de French markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van SAN is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1994 | 74,846 | Belen Garijo Lopez | www.sanofi.com |
Sanofi, een bedrijf in de gezondheidszorg, houdt zich bezig met onderzoek, ontwikkeling, productie en marketing van therapeutische oplossingen in de Verenigde Staten, Europa en internationaal. Het bedrijf levert immunologie en ontstekingen, zeldzame ziekten, neurologie, oncologie en andere geneesmiddelen en vaccins. Het biedt ook kindervaccins tegen poliomyelitis, pertussis en haemophilus influenzae type b (Hib); bescherming tegen respiratoir syncytieel virus en zeswaardige combinatievaccins tegen difterie, tetanus, pertussis, polio, Hib en hepatitis B; griep-, boost-, meningitis-, reis- en endemische vaccins, waaronder hepatitis A-, tyfus-, gele koorts- en rabiësvaccins.
Sanofi Samenvatting
| SAN fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €90.99b |
| Inkomsten(TTM) | €4.83b |
| Inkomsten(TTM) | €47.35b |
18.8x
Koers/Winstverhouding1.9x
P/S-verhoudingIs SAN overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| SAN resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €47.35b |
| Kosten van inkomsten | €13.09b |
| Brutowinst | €34.26b |
| Overige uitgaven | €29.44b |
| Inkomsten | €4.83b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Jul 30, 2026
| Winst per aandeel (EPS) | 4.02 |
| Brutomarge | 72.36% |
| Nettowinstmarge | 10.20% |
| Schuld/Eigen Vermogen Verhouding | 24.9% |
Hoe presteerde SAN op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
5.4%
Huidig dividendrendement102%
UitbetalingsratioBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/03 09:18 |
| Aandelenkoers aan het einde van de dag | 2026/07/03 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Sanofi wordt gevolgd door 50 analisten. 18 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |
| null null | Banco de Sabadell. S.A. |